Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis
Xconomy
JANUARY 9, 2020
Empirico, a biotech that has developed tools to analyze genomics data and use those insights to identify potential therapeutic targets, has signed a collaboration deal with antisense drug developer Ionis Pharmaceuticals that includes a $10 million equity investment. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Let's personalize your content